NCT05776134 2026-04-08
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel
Gilead Sciences
Available
Clinical Trials
37 trialsNCT05100134 2026-04-01
Managed Access Programs for LDK378, Ceritinib
Novartis
No longer available
NCT06915766 2026-03-09
Expanded Access to Bezuclastinib for Patients With NonAdvanced Systemic Mastocytosis or Advanced Systemic Mastocytosis
Cogent Biosciences, Inc.
Available
NCT07215832 2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available
NCT06799221 2026-02-27
Expanded Access Program for OOS Obe-cel
Autolus Limited
Available
NCT03123029 2026-01-30
Expanded Access to Venetoclax
AbbVie
Available
NCT07346105 2026-01-16
Orca-T Expanded Access Program Study for Patients With Advanced Hematologic Malignancies
Orca Biosystems, Inc.
Temporarily not available
NCT05619367 2025-12-23
A Compassionate Use (CU) Program of Odronextamab
Regeneron Pharmaceuticals
Available
NCT04400591 2025-12-11
Nonconforming Lisocabtagene Maraleucel Expanded Access Protocol
Juno Therapeutics, a Subsidiary of Celgene
Available
NCT03601442 2025-12-05
CTL019 Out of Specification MAP for ALL or DLBCL Patients
Novartis
Available
NCT05776160 2025-12-01
Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel
Gilead Sciences
Available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT04809233 2025-06-04
Expanded Access to Tipifarnib
Kura Oncology, Inc.
Available
NCT05738538 2025-06-04
Expanded Access to Ziftomenib
Kura Oncology, Inc.
Available
NCT01833039 2025-02-03
An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Janssen Biotech, Inc.
Approved for marketing
NCT05172700 2024-12-18
Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer
Eli Lilly and Company
Approved for marketing
NCT04052854 2024-10-23
A Single-Arm, Expanded Access Study of Zanubrutinib in Participants With B-cell Malignancies
BeiGene
No longer available
NCT05219266 2024-06-28
Managed Access Programs for PKC412, Midostaurin
Novartis
No longer available
NCT03592576 2024-05-06
Expanded Access to Navitoclax
AbbVie
No longer available
NCT04757259 2024-03-19
Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From Cerdulatinib
Alexion Pharmaceuticals, Inc.
No longer available
NCT03153462 2023-11-08
ZUMA-9
Gilead Sciences
Approved for marketing
NCT02822495 2023-06-15
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Atara Biotherapeutics
No longer available
NCT05733650 2023-05-25
Expanded Access Program for Epcoritamab
Genmab
Approved for marketing
NCT05131438 2023-03-27
An Expanded Access Program to Provide Sugemalimab for the Treatment of Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (R/R ENKTL)
EQRx International, Inc.
No longer available
NCT05692050 2023-02-03
Expanded Access to Epcoritamab
AbbVie
No longer available
NCT00419367 2022-09-22
Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042)
Merck Sharp & Dohme LLC
No longer available
NCT04559555 2022-08-09
MAP to Provide Access to Nilotinib, for Patients With Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Novartis
No longer available
NCT04162756 2021-10-14
ZUMA-18
Gilead Sciences
Approved for marketing
NCT04943952 2021-08-03
JZP458 - Recombinant Erwinia Asparaginase for Treatment of ALL / LBL Patients With Hypersensitivity to E. Coli-derived Asparaginase
Jazz Pharmaceuticals
Approved for marketing
NCT04705454 2021-05-12
Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
ADC Therapeutics S.A.
No longer available
NCT01196208 2020-09-21
A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001
Seagen Inc.
No longer available
NCT04300803 2020-08-28
Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL
MorphoSys AG
Approved for marketing
NCT02715843 2019-10-11
Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma
Molecular Templates, Inc.
No longer available
NCT02197650 2018-12-04
EAP
ERYtech Pharma
No longer available
NCT02437019 2017-03-20
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Janssen-Cilag Farmaceutica Ltda.
Approved for marketing
NCT00720603 2015-03-24
EAP
Sanofi
No longer available
NCT02136511 2014-10-28
Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia
Gilead Sciences
Approved for marketing